{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:58:38Z","timestamp":1785261518477,"version":"3.55.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Itraconazole is the preferred antifungal agent for mild to moderate histoplasmosis and step-down therapy following amphotericin B treatment. Although hydroxy-itraconazole, a major metabolite of itraconazole, displays antifungal activity comparable with that of the parent compound, its role in therapeutic drug monitoring targets for histoplasmosis remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The objective was to compare clinical outcomes and adverse events using itraconazole parent-compound concentrations alone versus combined itraconazole and hydroxy-itraconazole concentrations in patients treated for histoplasmosis. This retrospective cohort study included adults with probable or proven histoplasmosis who received itraconazole and had at least 1 documented serum concentration. The primary outcome was clinical response across 3 groups: (1) parent (itraconazole parent-compound concentration &gt;1.0 mcg\/mL), (2) combined (parent-compound concentration &lt;1.0 mcg\/mL with combined itraconazole plus hydroxy-itraconazole &gt;1.0 mcg\/mL), and (3) subtherapeutic (failure to reach either threshold). Treatment response and adverse events were analyzed using the Fisher exact test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 108 patients (parent, n = 40; combined, n = 40; subtherapeutic, n = 28), response rates differed across groups (parent (95%); combined (90%); subtherapeutic (67.9%);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006). There was no difference between the parent and combined groups. Adverse events did not differ, although drug discontinuation occurred more frequently in the subtherapeutic group (parent (5%); combined (20%); subtherapeutic (25%);\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Patients who failed to achieve either an itraconazole concentration &gt;1 mcg\/mL or a combined itraconazole plus hydroxy-itraconazole concentration &gt;1 mcg\/mL had lower response rates. Similar outcomes among patients achieving the itraconazole target alone and those achieving the combined target suggest that hydroxy-itraconazole concentrations may contribute to therapeutic drug monitoring targets in histoplasmosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001513","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:01:38Z","timestamp":1785258098000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective Analysis of Itraconazole and Hydroxy-Itraconazole Serum Concentrations Correlation to Clinical Outcomes of Histoplasmosis Treatment"],"prefix":"10.1097","author":[{"given":"Danielle","family":"Firkus","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic Health System, Eau Claire, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W.","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M.","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Enzler","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Haan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Duke University Hospital, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Herges","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Jannetto","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Vergidis","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8308-3264","authenticated-orcid":false,"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"R1-20260728","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis."},{"issue":"supplement 3","key":"R2-20260728","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/cid\/ciaf256","article-title":"2025 clinical practice guideline update by the Infectious Diseases Society of America on histoplasmosis: treatment of asymptomatic histoplasma pulmonary nodules (histoplasmomas) and mild or moderate acute pulmonary histoplasmosis in adults, children, and pregnant people","volume":"81","author":"Arnold","year":"2026","journal-title":"Clin Infect Dis."},{"key":"R3-20260728","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijantimicag.2018.03.017","article-title":"A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil","volume":"52","author":"Brilhante","year":"2018","journal-title":"Int J Antimicrob Agents."},{"key":"R4-20260728","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jac\/45.3.371","article-title":"Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro","volume":"45","author":"Odds","year":"2000","journal-title":"J Antimicrob Chemother."},{"key":"R5-20260728","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R6-20260728","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/myc.13565","article-title":"Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis","volume":"66","author":"Firkus","year":"2023","journal-title":"Mycoses"},{"key":"R7-20260728","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis."},{"key":"R8-20260728","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/FTD.0000000000000438","article-title":"Reliable and easy-to-use liquid chromatography-tandem mass spectrometry method for simultaneous analysis of fluconazole, isavuconazole, itraconazole, hydroxy-itraconazole, posaconazole, and voriconazole in human plasma and serum","volume":"39","author":"M\u00fcller","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R9-20260728","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1515\/cclm-2016-0418","article-title":"A rapid UPLC-MS\/MS assay for simultaneous measurement of fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole concentrations in serum","volume":"55","author":"Basu","year":"2017","journal-title":"Clin Chem Lab Med."},{"key":"R11-20260728","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.clpt.6100230","article-title":"Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo","volume":"83","author":"Templeton","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"R12-20260728","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/dmd.104.000315","article-title":"Role of itraconazole metabolites in CYP3A4 inhibition","volume":"32","author":"Isoherranen","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"R13-20260728","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/phar.70021","article-title":"Correction of posaconazole concentrations for hypoalbuminemia","volume":"45","author":"Nix","year":"2025","journal-title":"Pharmacotherapy"},{"key":"R14-20260728","doi-asserted-by":"crossref","first-page":"116775","DOI":"10.1016\/j.jpba.2025.116775","article-title":"The active metabolite hydroxyitraconazole has substantially higher in vivo free fraction and free concentrations compared to itraconazole","volume":"259","author":"Iwao","year":"2025","journal-title":"J Pharm Biomed Anal."},{"key":"R15-20260728","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/jac5.1819","article-title":"\u201cHow to\u201d guide for pharmacist-led implementation of beta-lactam therapeutic drug monitoring in the critically ill","volume":"6","author":"Ausman","year":"2023","journal-title":"J Am Coll Clin Pharm."},{"key":"R16-20260728","doi-asserted-by":"crossref","first-page":"ofad468","DOI":"10.1093\/ofid\/ofad468","article-title":"Antifungal therapeutic drug monitoring practices: results of an Emerging Infections Network Survey","volume":"10","author":"Benedict","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"R17-20260728","doi-asserted-by":"crossref","first-page":"e01245-19","DOI":"10.1128\/AAC.01245-19","article-title":"Impact of triazole therapeutic drug monitoring availability and timing","volume":"63","author":"McCreary","year":"2019","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:01:40Z","timestamp":1785258100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001513","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"2026-03-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}